Physician profile
James W Howell
NPI 1134315443
$7,393.45
in general payments reported to CMS, 2019-2025
41 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $1,185 · 2021: $1,521 · 2022: $1,119 · 2023: $1,084 · 2024: $999 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.46 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $967.69 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $697.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $659.52 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $386.29 | 2019-2025 | |
| Lilly USA, LLC | $371.17 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $305.94 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.73 | 2019-2024 | Jardiance |
| Amgen INC. | $244.41 | 2019-2024 | Otezla, Repatha |
| Dexcom, INC. | $239.40 | 2021-2025 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $208.92 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.17 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $161.13 | 2019-2023 | Verquvo, Belsomra, Januvia |
| Otsuka America Pharmaceutical, INC. | $135.30 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $119.30 | 2019-2024 | Veozah, Myrbetriq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.